A practical reference on thymosin beta-4: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.
This page was last updated on 2026-07-27 and is reviewed periodically as new material appears.
Controlled human trials of the short fragment are scarce. Much of what appears in review articles is extrapolated from animal models or from studies of the parent protein, and literature searches return a larger body of cardiac and ophthalmic work on thymosin beta-4 than on the abbreviated peptide. Regulatory treatment differs by jurisdiction, and in several countries the material is handled as a research chemical rather than an approved therapeutic. Statements about human benefit should be read as provisional.
Biological interest in this peptide centers on its relationship to actin dynamics. Thymosin beta-4 binds monomeric actin through an LKKTET motif, and a short sequence carrying that motif can compete with other actin-binding proteins in cell-free preparations. Investigators propose that such competition shifts the balance between filament assembly and disassembly, which in turn affects how readily a cell extends protrusions and migrates. Most of the supporting observations come from cultured cells and purified protein systems rather than from intact organisms.
Lyophilised material is stable for extended periods when kept dry and cold, and suppliers typically recommend storage well below freezing. Once dissolved, the peptide is handled at refrigeration temperatures and used within a short period, because peptide bonds and the acetylated terminus can be affected by repeated freeze-thaw cycles, proteases, or extreme pH. Bacteriostatic water and saline are both described as solvents, although preservatives can interfere with some analytical workflows. Reconstituted solutions are inspected for particulates before use.
Sports authorities classify the peptide as a prohibited substance, and it appears on the World Anti-Doping Agency list under peptide hormones, growth factors, and related substances. Racing jurisdictions for horses and dogs have issued separate restrictions, and several national bodies treat it as a controlled or prescription-only item. As a research chemical it is sold without a therapeutic indication, and labels usually state that the product is not for human or veterinary use. Regulatory treatment therefore varies by country.
| Property | Value | Notes |
|---|---|---|
| Common synonyms | Thymosin beta-4 fragment; TB4 fragment | Naming is inconsistent across suppliers and publications |
| Reported sequence | Ac-LKKTETQ | Corresponds to residues 17-23 of the parent protein |
| Frequently cited registry number | 77591-33-4 | Associated with full-length thymosin beta-4 rather than the fragment |
| Common supplied form | Freeze-dried solid | Often presented as an acetate or trifluoroacetate salt |
| Regulatory treatment | Varies by country | Frequently handled as a research chemical; not broadly approved as a therapeutic |
Research interest in thymosin beta-4 fragments centres on actin sequestration, cell migration and tissue repair models. Most published work uses cultured cells or animal wound and cardiac preparations, and findings are generally described as preliminary. No fragment of this protein has been approved as a therapeutic product by major regulators. Reviews of the field note inconsistent dosing, delivery routes and outcome measures across studies, which complicates direct comparison. The material is best understood as a laboratory reagent with an active but unresolved research literature.
TB-500 is a catalogue name applied to a synthetic peptide related to thymosin beta-4, an actin-binding protein found in most mammalian cells. Suppliers do not use the label consistently: some describe it as the full 43-residue protein, others as a short fragment from the actin-binding region, and others as a related tetrapeptide. Because the name is commercial rather than chemical, two products sold under it may not contain the same molecule. This naming ambiguity is the first point to check in any description of the material.
Thymosin beta-4 is a 43-residue actin-binding protein found in most mammalian cell types, where it participates in cytoskeletal regulation and cell migration. TB-500 represents only a short fragment of that protein and does not include the remaining residues. Whether the isolated fragment reproduces the full range of activities reported for the intact protein remains an open question. Researchers commonly treat the two as related but distinct entities when comparing results.
Published work involving this sequence spans actin-binding assays, cell-migration studies, wound-healing models, and cardiovascular or musculoskeletal experiments. Much of the biological rationale derives from in vitro systems and animal models, and the number of controlled human studies is small. Reported outcomes vary across preparations, doses, and routes, which complicates comparison between studies. Reviews generally describe the evidence base as preliminary rather than settled. Mechanistic explanations are often proposed by analogy to the parent protein rather than demonstrated directly.
Discussion of TB-500 appears in several distinct literatures that rarely cite one another. Peer-reviewed studies usually describe in vitro assays or small animal experiments and are cautious about extrapolation. Veterinary and sports communities circulate anecdotal reports with limited methodological detail. Commercial listings add a third layer, often using the name interchangeably with thymosin beta-4 even though the two molecules differ in size and sequence. Regulatory status varies by country, and the compound is not a licensed medicine in most jurisdictions, so readers comparing sources should check which molecule and which purity each source actually describes.
TB-500 is a synthetic seven-residue peptide whose sequence, LKKTETQ, matches the N-terminal actin-binding region of thymosin beta-4. It is usually supplied in an N-terminally acetylated form, a modification that blocks the free amino terminus and can influence behavior in solution. In the research literature the same sequence appears under several names, including thymosin beta-4 fragment and shortened thymosin beta-4. Because it is a short peptide rather than the full 43-residue parent protein, its measured properties differ from those reported for thymosin beta-4 as a whole, and the two are not interchangeable in experimental design.
Literature and online discussion often conflate TB-500 with full-length thymosin beta-4, even though the two differ in size and are not interchangeable in analytical terms. The fragment is produced by solid-phase peptide synthesis, and the product is a defined seven-residue chain rather than a biological extract. Because the term is a trade-style label, two vendors may supply materials of the same nominal sequence but different counter-ion content, purity, or water content. Comparisons across studies are therefore difficult unless the exact sequence and purity are reported.
TB-500 is a research peptide whose sequence matches residues 17 to 23 of thymosin beta-4, a 43-residue protein present in most mammalian cells. The chain is seven amino acids long, written as LKKTETQ, and is normally supplied with an acetyl group on the N-terminus. Suppliers list it as a lyophilised powder under the code name TB-500, and the same sequence appears elsewhere in catalogues as the thymosin beta-4 actin-binding fragment. The label is commercial rather than systematic, so no single authority fixes exactly what TB-500 denotes.
Attachment of alkyl groups to DNA bases, resulting in the DNA being fragmented by repair enzymes in their attempts to replace the alkylated bases, preventing DNA synthesis and RNA transcription from the affected DNA. DNA damage via the formation of cross-links which prevents DNA from being separated for synthesis or transcription. Induction of mispairing of the nucleotides leading to mutations. The precise mechanisms by which chlorambucil acts to kill tumor cells are not yet completely understood.
Shaw Industries, one of the world's largest carpet manufacturers, has been noted for their commitment to "cradle to cradle" sustainability, with programs for reclamation of end-of-use flooring and a focus on products which are designed to be recyclable. In the 2010s and 2020s, societal awareness of widespread microplastic pollution and its adverse impacts on human health and wildlife (especially aquatic and marine) increased. A significant contributing factor is how long most plastics, including nylons, take to fully degrade to component chemicals in the natural environment (anywhere from decades to millennia), while being prone to fragmenting into smaller particles which cannot easily be removed from ecosystems.
=== Infectious disease applications === PCR allows for rapid and highly specific diagnosis of infectious diseases, including those caused by bacteria or viruses. PCR also permits identification of non-cultivatable or slow-growing microorganisms such as mycobacteria, anaerobic bacteria, or viruses from tissue culture assays and animal models. The basis for PCR diagnostic applications in microbiology is the detection of infectious agents and the discrimination of non-pathogenic from pathogenic strains by virtue of specific genes. Characterization and detection of infectious disease organisms have been revolutionized by PCR in the following ways:
== Culinary uses == Onion powder may be used as a seasoning atop a variety of foods and dishes, such as pasta, pizza, and grilled chicken. It is a primary ingredient in beau monde seasoning. and is sometimes used as a meat rub. Onion powder is also an ingredient in some commercially prepared foods, such as sauces, soups, and salad dressings. Additionally, it can be used in various recipes like burgers or meatloaf. Onion salt is used as a seasoning on finished dishes and as an ingredient in many types of dishes, such as meat and vegetable dishes, casseroles and soups.
Sources: en.wikipedia.org
=== Judges' Costumes === Episode 1: Carla Hall as a bloody victim, Zac Young as Chucky, Stephanie Boswell as the final girl Episode 2: Carla Hall and Stephanie Boswell as terrifying twins (inspired by the Grady Twins from The Shining), Zac Young as an archaeologist (inspired by Indiana Jones) Episode 3: Carla Hall as an evil cheerleader, Zac Young as a vampire glam rock star, Stephanie Boswell as Mistress of the Dark (inspired by Elvira) Episode 4: Carla Hall as an undead fitness instructor, Zac Young as a voodoo doll, Stephanie Boswell as goblin king (inspired by Jareth from the 1986 movie Labyrinth) Episode 5: Carla Hall as dancing queen who only made it to seventeen, Zac Young as tuxedo wolfman, Stephanie Boswell as bloody prom queen (inspired by Carrie White) Episode 6: Carla Hall as deadly disco queen, Zac Young as vicious poodle, Stephanie Boswell as creepy clown Episode 7: Carla Hall as cat lady, Zac Young as devilish boss, Stephanie Boswell as Dollface
== History == Diabulimia is not currently recognised in the DSM-5. Current diagnoses are based on the idea of insulin restriction being a feature of existing anorexia nervosa and bulimia nervosa. Diabulimia is gaining notability within scientific research. In 2019, NHS England began trialling specialist diabulimia clinics. Whilst access to eating disorder clinics is improving, access to specialist diabulimia services is not widely available.
ClickSeq, a method for generating next generation sequencing libraries two-dimensional gel electrophoresis separation preparative organic synthesis of 1,4-substituted triazoles modification of peptide function with triazoles modification of natural products and pharmaceuticals natural product discovery macrocyclizations using Cu(I) catalyzed triazole couplings modification of DNA and nucleotides by triazole ligation supramolecular chemistry: calixarenes, rotaxanes, and catenanes dendrimer design carbohydrate clusters and carbohydrate conjugation by Cu(1) catalyzed triazole ligation reactions synthesis of polymers and biopolymers attachment of molecular machinery to solid surfaces material science nanotechnology biomaterials
The revolts culminated with the revolt in East Germany against the Marxist–Leninist regime of Erich Honecker and demands for the Berlin Wall to be torn down. The event in East Germany developed into a popular mass revolt with sections of the Berlin Wall being torn down and East and West Berliners uniting. Gorbachev's refusal to use Soviet forces based in East Germany to suppress the revolt was seen as a sign that the Cold War had ended. Honecker was pressured to resign from office and the new government committed itself to reunification with West Germany. The Marxist–Leninist regime of Nicolae Ceaușescu in Romania was forcefully overthrown in 1989 and Ceaușescu was executed. Almost Eastern Bloc regimes also fell during the Revolutions of 1989 (1988–1993). Unrest and eventual collapse of Marxism–Leninism also occurred in Yugoslavia, although for different reasons than those of the Warsaw Pact. The death of Josip Broz Tito in 1980 and the subsequent vacuum of strong leadership amidst an economic crisis allowed the rise of rival ethnic nationalism in the multinational country. The first leader to exploit such nationalism for political purposes was Slobodan Milošević, who used it to seize power as president of Serbia and demanded concessions to Serbia and Serbs by the other republics in the Yugoslav federation.
Amyloid-beta precursor protein (APP) is an integral membrane protein expressed in many tissues and concentrated in the synapses of neurons. It functions as a cell surface receptor and has been implicated as a regulator of synapse formation, neural plasticity, antimicrobial activity, and iron export. It is coded for by the gene APP and regulated by substrate presentation. APP is best known as the precursor molecule whose proteolysis generates amyloid beta (Aβ), a polypeptide containing 37 to 49 amino acid residues, whose amyloid fibrillar form is the primary component of amyloid plaques found in the brains of Alzheimer's disease patients.
Sources: en.wikipedia.org
The leading proposal involves sequestration of monomeric actin, which would alter cytoskeletal turnover and cell movement. The actin-binding motif shared with the parent protein is central to that idea. Direct confirmation in whole organisms remains limited.
Very few controlled human studies focus on the seven-residue sequence itself. Most clinical data concern the full-length protein in cardiac or ophthalmic settings. Conclusions drawn for one form should not be assumed to transfer to the other.
Detection normally relies on reversed-phase liquid chromatography paired with mass spectrometry. Chromatographic retention time establishes the expected elution window, and the mass spectrum confirms the molecular ion. Immunoassays exist but can cross-react with related peptides.
The most common approach is liquid chromatography with tandem mass spectrometry after extraction from blood or urine. Immunoassays exist but are generally treated as screening tools because of cross-reactivity.